The Trump administration's effort to impose new requirements on Novavax's COVID-19 vaccine — the nation's only traditional ...

Novavax Inc. closed 72.05% short of its 52-week high of $23.86, which the company reached on June 6th.

The US Food and Drug Administration has discussed with vaccine-maker Novavax the need for an additional trial of its Covid-19 ...

Comments over the weekend by FDA chief Martin Makary suggest the agency views Novavax’s updated COVID shot as a “new product” ...

Novavax shows financial improvement but faces vaccine challenges. Read why I rated NVAX stock as 'Hold' and what risks and ...

Thousands of Americans campaigning for the Novavax COVID-19 booster got some good news this week: the FDA signaled it might ...

Novavax's protein-only vaccine is once again expected to move from emergency approval to full approval status following a pause.

Federal regulators have asked Novavax to complete an additional clinical trial on its COVID-19 vaccine after previously ...

Novavax Inc. closed 73.09% below its 52-week high of $23.86, which the company achieved on June 6th.

Novavax faces uncertainty as FDA requests a new clinical trial for its COVID-19 vaccine, the last protein-based option in the ...

The President Donald Trump administration's request for Novavax Inc. to conduct new clinical trials for its COVID-19 vaccine ...

The FDA is asking Novavax for a non-mandatory postmarketing commitment to produce additional clinical data for its ...